View Item 

Show simple item record

The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease
dc.contributor.authorNojkov, B.en_US
dc.contributor.authorRubenstein, Joel H.en_US
dc.contributor.authorAdlis, Susan A.en_US
dc.contributor.authorShaw, M. J.en_US
dc.contributor.authorSaad, Richard J.en_US
dc.contributor.authorRai, J.en_US
dc.contributor.authorWeinman, B.en_US
dc.contributor.authorChey, William D.en_US
dc.date.accessioned2010-06-01T20:16:21Z
dc.date.available2010-06-01T20:16:21Z
dc.date.issued2008-03en_US
dc.identifier.citationNOJKOV, B.; RUBENSTEIN, J. H.; ADLIS, S. A.; SHAW, M. J.; SAAD, R.; RAI, J.; WEINMAN, B.; CHEY, W. D. (2008). "The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease." Alimentary Pharmacology & Therapeutics 27(6): 473-482. <http://hdl.handle.net/2027.42/73392>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73392
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18194508&dopt=citationen_US
dc.format.extent127104 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rightsJournal compilation © 2008 Blackwell Publishing Ltden_US
dc.titleThe influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux diseaseen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum* Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, MI, USAen_US
dc.contributor.affiliationother† Health Research Center, Institute for Research and Education, Park Nicollet Clinic, Health System Minnesota, MN, USAen_US
dc.identifier.pmid18194508en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73392/1/j.1365-2036.2008.03596.x.pdf
dc.identifier.doi10.1111/j.1365-2036.2008.03596.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceAgreus L, Svardsudd K, Talley NJ, Jones MP, Tibblin G. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol 2001; 96: 2905 – 14.en_US
dc.identifier.citedreferenceLocke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmstead County, Minnesota. Gastroenterology 1997; 112: 1448 – 56.en_US
dc.identifier.citedreferenceChiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798 – 810.en_US
dc.identifier.citedreferenceDeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100: 190 – 200.en_US
dc.identifier.citedreferenceChey WD, Inadomi JM, Booher A, Sharma VK, Ferdrick AM, Holden CW. Primary care physicians perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol 2005; 100: 1243 – 50.en_US
dc.identifier.citedreferenceGalmiche JP. Non-erosive reflux disease and atypical gastro-oesophageal reflux disease manifestations: treatment results. Drugs 2006; 66 ( Suppl. 1 ): 7 – 13; Discussion 29–33.en_US
dc.identifier.citedreferenceQadeer MA, Phillips CO, Lopez AR, et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101: 2646 – 54.en_US
dc.identifier.citedreferenceHirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007; 102: 668 – 85.en_US
dc.identifier.citedreferenceMartinez SD, Malagon IB, Garewall HS, Cui H, Fass R. Non-erosive reflux disease (NERD) – acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17: 537 – 45.en_US
dc.identifier.citedreferenceMainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance–pH monitoring. Gut 2006; 55: 1398 – 402.en_US
dc.identifier.citedreferenceLocke GR, Zinsmeister AR, Fett SL, Melton LJ 3rd, Talley NJ. Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil 2005; 17: 29 – 34.en_US
dc.identifier.citedreferenceLee YC, Wang HP, Chiu HM, et al. Comparative analysis between psychological and endoscopic profiles in patients with gastroesophageal reflux disease: a prospective study based on screening endoscopy. J Gastroenterol Hepatol 2006; 21: 798 – 804.en_US
dc.identifier.citedreferenceBaker LH, Lieberman D, Oehlke M. Psychological distress in patients with gastroesophageal reflux disease. Am J Gastroenterol 1995; 90: 1797 – 803.en_US
dc.identifier.citedreferenceStanghellini V. Relationship between upper gastrointestinal symptoms and lifestyle, psychosocial factors and comorbidity in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol 1999; 231: 29 – 37.en_US
dc.identifier.citedreferenceAvidan B, Sonnenberg A, Giblovich H, Sontag SJ. Reflux symptoms are associated with psychiatric disease. Aliment Pharmacol Ther 2001; 15: 1907 – 12.en_US
dc.identifier.citedreferenceWong WM, Lai KC, Lam KF, et al. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther 2003; 18: 595 – 604.en_US
dc.identifier.citedreferenceNaliboff BD, Mayer M, Fass R, et al. The effect of life stress on symptoms of heartburn. Psychosom Med 2004; 66: 426 – 34.en_US
dc.identifier.citedreferenceDean BB, Gano AD, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656 – 64.en_US
dc.identifier.citedreferenceCarlsson R, Dent J, Watts R, et al. Gastro-esophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroentrol Hepatol 1998; 10: 119 – 24.en_US
dc.identifier.citedreferenceJohnsson F, Hatlebakk JG, Klintenberg AC, Roman J. Symptom relieving effect of esomeprazole 40 mg daily in patients with heartburn. Scand J Gastroenterol 2003; 38: 347 – 53.en_US
dc.identifier.citedreferenceChey WD. Erosive esophagitis and NERD: can we really classify patients with heartburn using endoscopic findings? Clin Gastroenterol Hepatol 2004; 2: 654 – 5.en_US
dc.identifier.citedreferenceShaw MJ, Talley NJ, Beebe TJ, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001; 96: 52 – 7.en_US
dc.identifier.citedreferenceShaw M, Talley NJ, Adlis S, Beebe T, Tomshine P, Healey M. Development of a digestive health status instrument: tests of scaling assumptions, structure and reliability in a primary care population. Aliment Pharmacol Ther 1998; 12: 1067 – 78.en_US
dc.identifier.citedreferenceShaw MJ, Beebe TJ, Adlis SA, Talley NJ. Reliability and validity of the digestive health status instrument in samples of community, primary care, and gastroenterology patients. Aliment Pharmacol Ther 2001; 15: 981 – 7.en_US
dc.identifier.citedreferenceWiklund IK, Junghard O, Grace E, et al. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl 1998; 583: 41 – 9.en_US
dc.identifier.citedreferenceDerogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med 1983; 13: 595 – 605.en_US
dc.identifier.citedreferenceDent J, Brun J, Fendrick AM, et al. An evidence based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999; 44 ( Suppl. 2 ): S1 – 16.en_US
dc.identifier.citedreferenceManning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2: 653 – 4.en_US
dc.identifier.citedreferenceNastaskin I, Mehdikhani E, Conklin J, Park S, Pinentel M. Studying the overlap between IBS and GERD: a systematic review of the literature. Dig Dis Sci 2006; 51: 2113 – 20.en_US
dc.identifier.citedreferenceMoayyedi P, Talley NJ. Gastroesophageal reflux disease. Lancet 2006; 367: 2086 – 100.en_US
dc.identifier.citedreferenceDrossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 1569 – 80.en_US
dc.identifier.citedreferenceDickman R, Feroze H, Fass R. Gastroesophageal reflux disease and irritable bowel syndrome: a common overlap syndrome. Curr Gastroenterol Rep 2006; 8: 261 – 5.en_US
dc.identifier.citedreference33 Prevalence and treatment of mental health problems. In: Substance Abuse and Mental Health Services Administration. Results from the 2003 National Survey on Drug Use and Health: National Findings. [monograph on the Internet] Rockville, MD: Office of Applied Studies, NSDUH Series H–25, DHHS Publication No. SMA 04–3964; 2006: [cited 2007 Dec 19]. Available from: http://www.oas.samhsa.gov/NHSDA/2k3NSDUH/2k3results.htm#ch8en_US
dc.identifier.citedreferenceSpitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. JAMA 1999; 282: 1737 – 44.en_US
dc.identifier.citedreferencePogromov AP, Diukova GM, Rykova SM, Bein AM. Psycho-autonomic aspects in patients with gastroesophageal reflux disease, and functional esophageal disorders. Klin Med 2005; 83: 41 – 4.en_US
dc.identifier.citedreferenceCorsetti M, Caenepeel P, Fischler B, Janssens J, Tack J. Impact of coexisting irritable bowel syndrome on symptoms and pathophysiological mechanisms in functional dyspepsia. Am J Gastroenterol 2004; 99: 1152 – 9.en_US
dc.identifier.citedreferenceFass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease – where next? Aliment Pharmacol Ther 2005; 22: 79 – 94.en_US
dc.identifier.citedreferenceMertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40 – 52.en_US
dc.identifier.citedreferenceTrimble KC, Douglas S, Pryde A, Heading RC. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for generalized disorder of gut sensitivity. Dig Dis Sci 1995; 40: 1607 – 13.en_US
dc.identifier.citedreferenceLind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2036.2008.03596.x.pdf
Size:
124.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.